{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T18:29:03Z","timestamp":1784658543476,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T00:00:00Z","timestamp":1508457600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s00535-017-1396-0","type":"journal-article","created":{"date-parts":[[2017,10,20]],"date-time":"2017-10-20T05:14:53Z","timestamp":1508476493000},"page":"566-575","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection"],"prefix":"10.1007","volume":"53","author":[{"given":"Hiromitsu","family":"Kumada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunamasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akio","family":"Ido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Takaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia","family":"Alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Redman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pugatch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami J.","family":"Pilot-Matias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preethi","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajneet K.","family":"Oberoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangang","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuaki","family":"Chayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,20]]},"reference":[{"issue":"3","key":"1396_CR1","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","volume":"9","author":"H Bennett","year":"2015","unstructured":"Bennett H, Waser N, Johnston K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9(3):378\u201390.","journal-title":"Hepatol Int"},{"issue":"Suppl 2","key":"1396_CR2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1478-3231.2011.02540.x","volume":"31","author":"W Sievert","year":"2011","unstructured":"Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61\u201380.","journal-title":"Liver Int"},{"issue":"4","key":"1396_CR3","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","volume":"57","author":"K Mohd Hanafiah","year":"2013","unstructured":"Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333\u201342.","journal-title":"Hepatology"},{"issue":"1 Suppl","key":"1396_CR4","first-page":"S65","volume":"15","author":"GG Liu","year":"2012","unstructured":"Liu GG, DiBonaventura M, Yuan Y, et al. The burden of illness for patients with viral hepatitis C: evidence from a national survey in Japan. Value Health. 2012;15(1 Suppl):S65\u201371.","journal-title":"Value Health"},{"issue":"3","key":"1396_CR5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1440-1746.2009.05789.x","volume":"24","author":"ML Yu","year":"2009","unstructured":"Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336\u201345.","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"1396_CR6","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","volume":"112","author":"G Fattovich","year":"1997","unstructured":"Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463\u201372.","journal-title":"Gastroenterology"},{"issue":"1","key":"1396_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1055\/s-2000-9506","volume":"20","author":"A Wasley","year":"2000","unstructured":"Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20(1):1\u201316.","journal-title":"Semin Liver Dis"},{"issue":"4","key":"1396_CR8","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62(4):1037\u201346.","journal-title":"Hepatology"},{"issue":"11","key":"1396_CR9","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762\u20138.","journal-title":"J Viral Hepat"},{"issue":"6","key":"1396_CR10","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1473-3099(15)70099-X","volume":"15","author":"M Mizokami","year":"2015","unstructured":"Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12\u00a0weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645\u201353.","journal-title":"Lancet Infect Dis"},{"key":"1396_CR11","unstructured":"The Japan Socieity of Hepatology. JSH Guidelines for the Management of Hepatitis C Virus Infection (5.4 Edition). 2017."},{"issue":"3","key":"1396_CR12","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/hep.24480","volume":"54","author":"V Martino Di","year":"2011","unstructured":"Di Martino V, Richou C, Cervoni JP, et al. Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: meta-analyses of randomized, controlled trials and implications for the future. Hepatology. 2011;54(3):789\u2013800.","journal-title":"Hepatology"},{"key":"1396_CR13","unstructured":"PEGASUS, Package Insert version 18, March 2015; Chugai Pharmaceutical Co., Ltd."},{"key":"1396_CR14","unstructured":"PEGINTRON Powder for Injection, Package Insert version 14, January 2016; MSD KK."},{"issue":"21","key":"1396_CR15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMoa1316145","volume":"370","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCG genotype 2 and 3. N Engl J Med. 2014;370(21):1993\u20132001.","journal-title":"N Engl J Med"},{"issue":"5","key":"1396_CR16","doi-asserted-by":"crossref","first-page":"e02558-16","DOI":"10.1128\/AAC.02558-16","volume":"61","author":"TI Ng","year":"2017","unstructured":"Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61(5):e02558-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"1396_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1391-5","author":"K Chayama","year":"2017","unstructured":"Chayama K, Suzuki F, Karino Y, et al. Efficacy and safety of glecaprevir\/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 2017. doi:\n                        10.1007\/s00535-017-1391-5\n                        \n                    .","journal-title":"J Hepatol"},{"key":"1396_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29510","author":"K Chayama","year":"2017","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and Safety of Glecaprevir\/Pibrentasvir in Japanese Patients with Chronic Genotype 2 Hepatitis C Virus Infection. Hepatology. 2017. doi:\n                        10.1002\/hep.29510\n                        \n                    .","journal-title":"J Hepatol"},{"issue":"3","key":"1396_CR19","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/hep.26388","volume":"58","author":"F McPhee","year":"2013","unstructured":"McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58(3):902\u201311.","journal-title":"Hepatology"},{"issue":"10","key":"1396_CR20","doi-asserted-by":"crossref","first-page":"e0165339","DOI":"10.1371\/journal.pone.0165339","volume":"11","author":"J Itakura","year":"2016","unstructured":"Itakura J, Kurosaki M, Hasebe C, et al. Complex pattern of resistance-associated substitutions of hepatitis C virus after daclatasvir\/asunaprevir treatment failure. PLoS ONE. 2016;11(10):e0165339.","journal-title":"PLoS ONE"},{"issue":"suppl","key":"1396_CR21","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(17)30432-4","volume":"66","author":"F Poordad","year":"2017","unstructured":"Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16\u00a0weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure. J Hepatol. 2017;66(suppl):S83\u20134.","journal-title":"J Hepatol"},{"issue":"Suppl","key":"1396_CR22","first-page":"1125A","volume":"64","author":"E Gane","year":"2016","unstructured":"Gane E, Lawitz E, Pugatch D, et al. EXPEDITION-4: efficacy and safety of glecaprevir\/pibrentasvir (ABT-493\/ABT-530) in patients with renal impairment and chronic hepatitis C virus genotype 1\u20136 infection. Hepatology. 2016;64(Suppl):1125A.","journal-title":"Hepatology"},{"issue":"suppl","key":"1396_CR23","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0168-8278(17)30326-4","volume":"66","author":"GR Foster","year":"2017","unstructured":"Foster GR, Gane E, Asatryan A, et al. ENDURANCE-3: safety and efficacy of glecaprevir\/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis. J Hepatol. 2017;66(suppl):S33.","journal-title":"J Hepatol"}],"updated-by":[{"DOI":"10.1007\/s00535-017-1409-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T00:00:00Z","timestamp":1510531200000}}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-017-1396-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-017-1396-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,3,24]],"date-time":"2018-03-24T23:31:07Z","timestamp":1521934267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-017-1396-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,20]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["1396"],"URL":"https:\/\/doi.org\/10.1007\/s00535-017-1396-0","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00535-017-1409-z","asserted-by":"object"}]},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,20]]}}}